Discovery and Development of Novel Therapeutics for Select Fungal Pathogens (R21/R33 Clinical Trial Not Allowed)
This grant supports early-stage research for developing new drugs to treat specific fungal infections caused by Candida auris, Aspergillus fumigatus, Coccidioides, and Mucorales. It uses a two-phase award system where progression to the second phase depends on achieving certain goals in the first phase.
Source
Dates
Keywords
Supporting Links
Documents
Similar Opportunities
-
NIAID cooperative agreement to implement investigator-led milestone-driven clinical trials (with possible mechanistic studies)
National Institutes of Health
-
DoD Rare Cancers Concept Award: fund highly innovative early concepts for rare cancer studies
Dept. of the Army -- USAMRAA
-
NIH R21 Exploratory/Developmental Grant — Clinical Trial Required
National Institutes of Health
-
FY26 Tick-Borne Disease Idea Development Award for innovative Lyme and other tick-borne research
Dept. of the Army -- USAMRAA
-
Rare Cancers Idea Development Award to advance early, high-impact research ideas
Defense Health Agency Contracting Activity - DHACA
Find tens of thousands more opportunities — free
Scout accounts are free. Sign up to browse the full funding database, unlock the solicitation links and documents for this opportunity, and see how well each one fits your organization.
-
Tens of thousands of funding opportunities
Search and filter every grant and solicitation in Scout — all free, no credit card required.
-
Instant Fit Analysis
Let our grant expert AI score how well this opportunity aligns with your organization, strengths, gaps, and how to improve your chances of winning funding.
-
Source links & full documents
Jump straight to the solicitation and download every attachment.
-
Save opportunities & track deadlines
Keep the opportunities that fit in one place and stay ahead of every due date.
Already have an account? Sign In
Trusted by 500+ Happy Customers